GP
TEVA icon

GLG Partners’s Teva Pharmaceuticals TEVA Stock Holding History

GLG Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-47,570
Closed -$1.72M – 516
2016
Q4 		$1.72M Sell
47,570
-3,914
-8% -$156K 0.07% 235
2016
Q3 		$2.37M Buy
51,484
+17,179
+50% +$896K 0.07% 273
2016
Q2 		$1.72M Sell
34,305
-825
-2% -$43.9K 0.05% 298
2016
Q1 		$1.88M Sell
35,130
-305,125
-90% -$17.9M 0.05% 274
2015
Q4 		$22.3M Sell
340,255
-132,716
-28% -$8.2M 0.71% 37
2015
Q3 		$26.7M Sell
472,971
-110,620
-19% -$7.17M 0.71% 34
2015
Q2 		$34.5M Buy
583,591
+463,134
+384% +$28.6M 0.89% 23
2015
Q1 		$7.5M Sell
120,457
-61,672
-34% -$3.59M 0.25% 123
2014
Q4 		$10.5M Sell
182,129
-557,106
-75% -$31M 0.31% 94
2014
Q3 		$39.7M Sell
739,235
-227,713
-24% -$12.1M 0.91% 19
2014
Q2 		$50.7M Buy
966,948
+727,830
+304% +$37.2M 1.21% 14
2014
Q1 		$12.6M Buy
239,118
+164,118
+219% +$7.59M 0.25% 114
2013
Q4 		$3.01M Hold
75,000
– – 0.21% 104
2013
Q3 		$2.83M Sell
75,000
-207,766
-73% -$8.1M 0.26% 101
2013
Q2 		$11.1M Buy
+282,766
New +$11M 0.42% 76

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

GLG Partners's TEVA Position: Q1 2017 in Review

GLG Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 47,570 shares — an estimated $1.72M sold.

GLG Partners first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $50.7M in Q2 2014. 688 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • GLG Partners reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • GLG Partners sold 47,570 Teva Pharmaceuticals shares in Q1 2017, an estimated $1.72M.
  • GLG Partners first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • GLG Partners's Teva Pharmaceuticals position peaked at $50.7M in Q2 2014.
  • 688 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on GLG Partners's 13F filing for Q1 2017, filed 15 May 2017.